The role of bone morphogenetic protein 2 in SMA-directed angiogenesis during distraction osteogenesis by Cheng, Thomas Wen-Tao
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2015
The role of bone morphogenetic
protein 2 in SMA-directed
angiogenesis during distraction
osteogenesis
https://hdl.handle.net/2144/16261
Boston University
   
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
Thesis 
 
 
 
 
 
THE ROLE OF BONE MORPHOGENETIC PROTEIN 2 IN SMA-DIRECTED 
ANGIOGENESIS DURING DISTRACTION OSTEOGENESIS  
 
 
 
 
by 
 
 
 
 
THOMAS W. CHENG 
 
B.S., Johns Hopkins University, 2013 
 
 
  
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Science 
 
2015  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2015 by 
 THOMAS W. CHENG 
 All rights reserved  
   
Approved by 
 
 
 
 
First Reader   
 Dr. Louis C. Gerstenfeld, Ph.D. 
 Professor, Department of Orthopaedic Surgery 
 
 
Second Reader   
 Dr. Beth Bragdon, Ph.D. 
Postdoctoral Research Fellow, Department of Orthopaedic Surgery 
 
 
 
 
 
ACKNOWLEDGMENTS 
I will like to thank my family for their support. I will like to express special 
appreciation to Dr. Gerstenfeld and Dr. Bragdon for giving me the opportunity to conduct 
research in the laboratory and being close mentors throughout this project.
 iv 
 
THE ROLE OF BONE MORPHOGENETIC PROTEIN 2 IN SMA-DIRECTED 
 
ANGIOGENESIS DURING DISTRACTION OSTEOGENESIS 
 
THOMAS W. CHENG 
 
ABSTRACT 
Bone is one of the few organs capable of regeneration after a substantial injury. 
As the bone heals itself after trauma, the coupling of angiogenesis to osteogenesis is 
crucial for the restoration of the skeletal tissue.  In prior studies we have shown that Bone 
Morphogenetic Protein 2 (BMP2), a potent agonist for skeletal formation is expressed by 
vessels making it a prime candidate that links the morphogenesis of the two tissues.  To 
investigate the role of BMP2 in the coordination of vessel and bone formation, we used a 
tamoxifen inducible Smooth Muscle Actin (SMA) promoter that conditionally expresses 
Cre recombinases crossed with a BMP2 floxed mouse in order to conditionally delete the 
BMP2 gene in smooth muscle actin (SMA) expressing cells. Using the mouse femur as 
our model for bone regeneration, we performed a surgical technique called distraction 
osteogenesis (DO) where an osteotomy is created followed by distraction or a gradual 
separation of the two pieces of bone. This primarily promotes intramembranous 
ossification at the osteotomy site by mechanical stimulation. Tamoxifen treatment started 
at day 6 and continued throughout the experiment. At post-operative days 3, 7, 12, 17, 24, 
and 31, we analyzed the bone and vessel formation by plain X-ray, micro-computed 
tomography (µCT) and vascular contrast enhanced µCT, and quantitative polymerase 
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chain reaction (qPCR) of selective genes. We assessed both the femur and surrounding 
tissue to obtain qualitative and quantitative assessments for skeletal and vascular 
formation. Our results demonstrated that the deletion of BMP2 in vascular tissue resulted 
in a reduction of angiogenesis in vivo followed by a decrease in skeletal tissue 
development. 
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INTRODUCTION 
Bone Cells 
  There are three main cell types that contribute to bone. They are called the 
osteoblasts, osteocytes, and osteoclasts (Mescher, 2013). The osteoblasts become 
osteocytes when the bone matrix, made of mainly type I collagen and calcium and 
phosphate crystals in the form of hydroxyapatite, that they produce eventually surrounds 
and traps themselves in a cavity called a lacunae (Takayanagi, 2007). Osteoblasts have 
proliferative potential and are associated primarily with the synthesis of new bone 
extracellular matrix  whereas the osteocytes are non-proliferative and are associated with 
the regulatory processes of mineral metabolism and mechano-signal transduction (Clarke, 
2008; Mescher, 2013; Takayanagi, 2007). The main role of the osteoblasts and osteocytes 
are anabolic and regulatory forming bone tissues whereas the osteoclasts are catabolic 
and resorb bone (Clarke, 2008). 
 
Modes of Bone Formation 
 Bone formation occurs through two process: endochondral and intramembranous 
osteogenesis. In endochondral ossification, cartilage tissue is first formed and then 
replaced with bone. There are various stages for this process starting with the recruitment 
of mesenchymal cells that then undergo differentiation into chondrocytes. The 
chondrocytes then undergo proliferation and start to secrete cartilage which is the 
template for bone to replace (Mackie et al., 2008). The chondrocytes then cease 
proliferation and become hypertrophic (Mackie et al., 2008). At this stage, the  1 
 
hypertrophic chondrocytes add collagen X to the extracellular matrix to allow for 
mineralization (Mackie et al., 2008). Blood vessels penetrate the cartilage to allow the 
cartilage to be mineralized by osteoblasts and the hypertrophic chondrocytes undergo 
apoptosis. Also at this time, the cartilage is reabsorbed by osteoclasts (Mackie et al., 
2008). This is seen in long bones such as a developing femur as it lengthens and matures. 
In intramembranous ossification involves direct bone formation from mesenchymal tissue 
without a cartilage base (Percival et al., 2013). It is shown in prior studies that Bone 
Morphogenetic Proteins (BMPs) are vital for intramembranous osteogenesis (Percival et 
al., 2013). This characteristic process occurs in bones such as flat bones located in the 
mandibular and the skull (Aronson, 1994).  
 
Fracture Statistics 
 Fractures occur when the bone is subjected to trauma which results in a break in 
the bone matrix (Marsell & Einhorn, 2011; Mescher, 2013). According to the CDC, in 
2010 there were 43 incidents of fractures overall for every 1,000 people, with people over 
age 75 having the highest rate of 115 per 1,000 (CDC, 2013). These staggering statistics 
not only results in expensive medical costs for treatment but also the medical expenses 
that follow complications. The total cost of male and female medical fees combined was 
$349 million in 2005 (CDC, 2013). It would be beneficial to understand the underlying 
mechanisms of bone repair in order to manipulate and decrease patient recovery time. 
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Distraction Osteogenesis 
Distraction osteogenesis (DO) is a surgical technique used to “apply controlled 
traction” to enhance the healing process and remodeling of bone (Natu et al., 2014). First 
introduced by Dr. Ilizarov in 1951, DO has been involved in various complicated 
orthopaedic cases such as mandibular defects, limb lengthening, and other craniofacial 
deformities (Ai-Aql, Alagl, Graves, Gerstenfeld, & Einhorn, 2008; Aronson, 1994; 
Makhdom & Hamdy, 2013).It is thought the physical stimulation caused by the 
mechanical forces during DO activates tissue growth (Natu et al., 2014).  
When applied to animal models, this surgical technique provides a unique 
opportunity for this study to investigate how BMP2 directs bone regeneration by 
measuring the temporal molecular events during bone regeneration. It differs from 
fractures in that the response is primarily bone driven lacking the development of 
extensive amount of cartilage tissue which is typical of the endochondral bone formation 
process associated with a fracture model. This allows us to be able to clearly see 
mechanisms that are related to intramembranous formation. 
 3 
  
Figure 1: The role of Bone Morphogenetic Proteins (BMPs) for bone formation. Process of bone healing once 
BMP2 has been placed at a specific site. Figure taken and adapted from Jain et al., 2013. 
 The DO procedure is separated into 3 phases: latency, distraction, and 
consolidation  which is shown in Figure 2 (Ai-Aql et al., 2008; Natu et al., 2014). During 
the latency phase, a hematoma is formed followed by inflammation and recruitment of 
mesenchymal stem cells as indicated by the presence of Il-1 and Il-6 which activate T 
cells (Dienz & Rincon, 2010; Lichtman et al., 1988). At the end of the latency phase, a 
callus is formed as first indicated by Sox9 then Acan then Col10a (Bi et al., 1999; Wigner 
et al., 2013). During the distraction phase, this callus is then stretched by the distraction 
device resulting in physical stimulation and further ossification as indicated by elevated 
of BMP2, the potent agonist for bone formation. At this stage, osteoblasts are actively 
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recruited to the site (Bais et al., 2009). Furthermore, vascular endothelial growth factors 
(VEGFs) especially VegfA are elevated to promote vessel formation to nourish the 
callous. In the consolidation phase, not shown in Figure 3, the bone is remodeled by the 
osteoclasts as shown by presence of RANKL and Cathepsin K (Takayanagi, 2007). Also, 
during the consolidation phase, serum markers for bone resorption has been identified as 
Trap5b (Shidara et al., 2008). As shown in Figure 3, there are various other biological 
processes with their accompanying cytokines and growth factors within each DO phase.  
 
Figure 2: Visual Summary of Distraction Osteogenesis Phases. The gray object represents the distraction device. 
(A) Latency phase of distraction osteogenesis. The red line indicates a transverse osteotomy (B) Distraction phase. The 
yellow parallelogram represents a formed callus (C) Consolidation. The green parallelogram represents new bone 
formation. 
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Figure 3: Distraction Osteogenesis Stages and Their Biological Processes. Figure taken from Ai-Aql et al., 2008. 
 
Bone Morphogenetic Proteins 
Bone Morphogenetic Proteins belongs to a superfamily of proteins called 
Transforming Growth Factor Beta (TGFβ) (Ai-Aql et al., 2008; Bragdon et al., 2011). A 
group of proteins from the BMP family were identified as the primary signaling molecule 
for bone regeneration. BMPs elicit their biological effects by binding to type I and type II 
serine/threonine kinase receptors which then activate the Smads pathway (Bragdon et al., 
2011). BMPs can also express their function by activating Smads-independent pathways 
(Bragdon et al., 2011). A multitude of cells related to maintaining the bone’s environment 
produce BMPs such as hypertrophic chondrocytes, osteoblasts, and smooth muscle cells 
(Bragdon et al., 2011).  
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Bone Morphogenetic Protein 2 (BMP2) is well established in the literature as a 
growth factor responsible for bone repair (Bragdon et al., 2011; Jain, Pundir, & Sharma, 
2013; Lissenberg-Thunnissen, De Gorter, Sier, & Schipper, 2011; Matsubara et al., 
2012). Osteoblasts produce BMP2 and depending on which cell the BMP2 binds to, it 
initiates chondrogenesis and osteogenesis. (Jain et al., 2013; Lissenberg-Thunnissen et 
al., 2011). If BMP2 binds to osteoprogenitors, it will cause differentiation to promote 
osteogenesis (Ogasawara et al., 2004). When BMP2 stimulates chondrocytes, it promotes 
chondrocytes to proliferate and maturation (Shu et al., 2011). Moreover, BMP2’s effects 
range from embryonic development of the heart to skeletal repair throughout life 
(Bragdon et al., 2011). 
 
Angiogenesis 
It is known that bone repair requires angiogenesis, the process that involves 
growth of new blood vessels (Kusumbe et al., 2014; Matsubara et al., 2012). There are 
two main types of angiogenesis: sprouting angiogenesis and intussusceptive 
angiogenesis, also known as splitting angiogenesis. The difference between sprouting and 
intussusceptive vessel formation is that the former involves de novo vessel formation and 
the later refers to new vessel elements by splitting mature vessels by inserting new 
extracellular matrix in the lumen of the vessel. However, it is only sprouting angiogenesis 
that has been associated with bone formation (Lu et al., 2006; Percival & Richtsmeier, 
2013). In this study, we focused on sprouting angiogenesis as there are no known markers 
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for intussusceptive angiogenesis even though angiopoietin 1 and 2 have been suggested 
to be identifiers for intussusceptive angiogenesis (Burri et al., 2004).  
The steps for sprouting angiogenesis involve degradation of capillary’s basement 
membrane followed by endothelial cell proliferation. The endothelial cells that direct 
angiogenesis are selected by the proximity the cell to the highest concentration of VegfA 
(Gerhardt, 2008). These cells, known as the tip cells, migrate towards the source of 
VegfA and the trail left behind is filled by proliferating endothelial cells. When the tissue 
is fully perfused the vessels are then stabilized by pericytes, a type of smooth muscle cell 
which contain smooth muscle actin, and the basement membrane is reformed. The 
pericytes lie within the basement membrane of the vessels beneath the endothelial cell 
(Otrock et al., 2007). 
Angiogenesis allows the fracture site to be fully nourished and presents signaling 
molecules through the vasculature that both support the progression of bone repair and 
then subsequent bone remodeling. (Matsubara et al., 2012). Recently, it was discovered 
that BMP2 is expressed by both smooth muscle cells and endothelia cells in vessels 
(Matsubara et al., 2012). This leads to questions as to the role that BMP2 plays in the new 
vessel formation during bone repair or in the tissues that are fed by these newly formed 
vessels during bone repair. Therefore, we crossed a tamoxifen inducible smooth muscle 
actin (SMA) Cre mouse with a BMP2 floxed mouse in order to conditionally delete the 
BMP2 gene in SMA positive cells. Several known angiogenesis markers are identified 
such as vascular endothelial-cadherin (ve-cadherin), vascular endothelial growth factor A 
(VegfA), vascular endothelial growth factor receptor 2 (VEGFR2), endomucin, and 
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platelet endothelial cell adhesion molecule (Pecam1) to track the development of new 
vessels.  
Ve-cadherin, also known as Cdh5, is a cadherin molecule displayed by 
endothelial cells (Adams & Alitalo, 2007). Cadherins molecules allow endothelial cells to 
tightly bind to each other to create an impermeable barrier to allow the endotheial cells to 
regulate moleculer transport across the lumen (Venkiteswaran et al., 2002). VEGFR2, 
also known as KDR, is a receptor for the VegfA molecule which is the strongest growth 
factor to stimulate angiogenesis (Otrock et al., 2007). Endomucin is another marker for 
angiogenesis as it is involved with focal adhesion assembly of endothelial cells (Ueno et 
al., 2001). Also, endomucin is known to associated in bone formation as indicated by its 
presence in vessels formed during osteogenesis (Kusumbe et al., 2014). Pecam1, also 
known as CD31, is prominetly used for immunohistological labelling for endothelial cells 
which are important cells involved in vessel formation (Parums et al., 1990). 
 
Cre-loxP System 
Due to embryonic lethality when using traditional genetic knockout of BMP2, we 
used a genetic strategy that bypasses this problem by using the Cre-loxP system (Bragdon 
et al., 2011; Haruyama, Cho, & Kulkarni, 2010). Cyclization recombinase (Cre), a 38 
kDa monomeric protein, is encoded by bacteriophage P1 (Ghosh & Duyne, 2002). The 
tyrosine recombinase identifies, binds, and cleave to the locus-X-over P1 (loxP) site 
which consists of a specific set of 34 base pair of DNA as shown in Figure 4. (Ghosh & 
Duyne, 2002; Pechisker, 2004).  
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Figure 4: Cre-lox system. The Cre binds to the recombinase binding element (RBE) located at the loxP site. The 
vertical arrows indicate where the Cre recombinase will cleave. Figure taken from Ghosh & Duyne, 2002. 
A tissue specific promoter can be implemented in mammalian models for 
conditional control of the Cre-loxP system (Kyrkanides, Miller, Bowers, & Federoff, 
2003). When activated, the Cre-lox system conditionally deletes the gene that is flanked 
by the loxP site in the specific cell types that are expressing the promoter driving the 
expression of Cre recombinase as shown in Figure 5. This molecular tool allows this 
study to investigate how the conditional deletion of BMP2 in smooth muscle actin 
expressing cells affects osteogenesis and angiogenesis in vivo.  
 
Figure 5: Tissue-specific Cre-loxP system. How the Cre/loxP system can be tissue/cell type specific by adding 
specific promoters. For our study, the cell type specific promoter is smooth muscle actin positive cells and it is 
inducible by tamoxifen. The target gene is the BMP2. When the two mice are crossed, it will create a strain of 
transgenic mouse containing SMA Cre x BMP2 flox. The Figure taken from Pechisker, 2004.  10 
 
In our studies we used a smooth muscle actin promoter to conditionally target the 
recombination of BMP2 in primarily vascular smooth muscle cells.  In these studies the 
SMA promoter was further temporally regulated by the addition of a tamoxifen inducible 
element that allowed us to only drive Cre from the SMA promoter after the induction by 
the addition of tamoxifen. 
Experimental Aims 
It is known that angiogenesis is required for proper bone healing and bone 
regeneration however the relationship between vessels and bone is not completely 
understood. Since BMP2 is known to be expressed in vessels by multiple cell types 
during DO, it is possible that BMP2 that is produced by these cells contributes to this 
link.  This study will identify relationships and roles of BMP2 signaling for angiogenesis 
and osteogenesis during DO. This is clinically relevant as knowledge of how BMP2 
operates can be used in the medical field in a precise way to modulate healing process. 
To investigate, we deployed an experimental timeline as shown in Figure 6 which 
includes distraction osteogenesis in conjunction with tamoxifen-induced BMP2 deletion 
in SMA expressing cells. 
 
Figure 6: Experimental Timeline. Experimental timeline where the blue box represents a latency period, red box 
represents the distraction period, green box represents a consolidation period, and yellow box represents the tamoxifen-
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induced BMP2 knockout phase. The top arrows indicate specific time points where we obtained x-ray, RNA, and µCT 
results. The day 6 arrow indicates beginning of tamoxifen or sterile corn oil injections. 
 The gene expression profiles for skeletal repair and angiogenesis will be collected 
for both femur and muscle that have known functions in skeletal repair and angiogenesis. 
Furthermore, X-ray images, µCT bone evaluation and µCT vessel perfusion scans will be 
conducted to gain an overall picture of how angiogenesis affects osteogenesis.   
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MATERIALS AND METHODS 
Animal Model 
 All animals used in this study met the requirements of an approved IACUC 
protocol which complies with all federal and USDA guidelines. The transgenic mouse 
model used for this study was originally from Dr. Steve Harris (Yang et al., 2012). All 
the mice used in the study were 13 to 15 weeks old male mice at the time of the surgical 
procedure. The transgenic strains of mice used are SMA Cre/BMP2 Flox; Rosa dTomato 
x SMA Cre BMP2 Flox; and LacZ Rosa x SMA BMP2 Flox. A total of 104 male mice 
were used for this study. Shown below in Table 1 are the time points and the number of 
samples per time point and their purpose. 
Time point Number of Samples Purpose 
Day 0 3 qPCR 
Day 3 3 qPCR 
Day 7 4 qPCR 
Day 12 11 qPCR 
Day 17 12 qPCR 
17 Bone evaluation 
10 Vessel perfusion 
5 Histology 
Day 24 6 qPCR 
4 Bone evaluation 
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1 Histology 
Day 31 7 qPCR 
13 Bone evaluation 
8 Vessel perfusion 
1 Histology 
Table 1: Enrollment of animals and their uses. 
List of Common Reagents Used  
 Common reagents and equipment used for this study are listed below in Table 2. 
Reagents Manufacturer 
Phosphate buffered saline (PBS), Taqman 
Reverse Transcription Kit, Universal 
Master Mix, and Appropriate Primers 
Applied Biosystems™ 
Enrofloxacin Baytril® 
Povidone-iodine  Betadine® 
Buprenorphine  Buprenex® 
Barium sulfate (Catalog No: 764) E-Z-EM Canada Inc. 
Curing agent for MicroFil and MicroFil Flow Tech, Inc. Carver, MA 
10% Phosphate buffered formalin, NaOH 
pellets, TAE buffer 
Fisher Scientific™ 
Isoflurane Henry Schein® 
Agarose, Chloroform, Ethanol, 
Ethylenediaminetetraacetic acid (EDTA), 
Sigma-Aldrich® 
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Gelatin, Hydrochloric Acid (HCl), 
Isopropanol, Paraformaldehyde (PFA), 
and Tamoxifen 
Table 2: Common reagents and equipment used for the study. Listed in this table are reagents and equipment 
regularly used for the study along with their respective manufacturer. The table is organized in alphabetical order with 
respect to the reagents and equipment. 
 
Surgical Procedure for Distraction Osteogenesis 
 Surgical procedures were performed in a chemical fume hood and was maintained 
with a non-fenestrated sterile field (Busse Inc.) and absorbant bench underpad (VWR®). 
Mice were anesthetized with 4% isoflurane /oxygen mixture using the Isotec 3 machine 
(Ohmeda®). Once unresponsive to physical stimuli, mice were maintained at 2% 
isoflurane/oxygen mixture and heat was provided with a heating pad to maintain 
homeostasis.  
 Mice received pre-operative analgesia (0.1mL buprenorphine) and antibiotic 
(0.01mL of enrofloxacin). The left limb was shaved and cleaned using povidone-iodine.  
An incision of one inch was made parallel to the femur from the greater trochanter to the 
knee (Lybrand, Bragdon, & Gerstenfeld, 2015). The femur was exposed by opening the 
muscle fascia layer posterior and anterior to the femur (Lybrand et al., 2015). The 
distraction device was opened to an approximate length of 3.0mm. The distraction device 
was then attached to the femur using 0.012 inch thin stainless steel wires (Standard 
Kobayashi Hooks) threaded at the greater trochanter and another wire posterior to the 
femur at the knee (Lybrand et al., 2015). A second set of wires were used to secure the 
distraction device in place using the same process. Once the distraction device was  15 
 
securely fastened, a tissue elevator was positioned to protect the surrounding muscle 
tissue and a transverse osteotomy was created using a hand grinder (Model: Gx-7, 
A.M.D. Dental Mfg., Inc.) with a circular saw attachment (Brasseler USA® Lot No. 
J4271). The fascia was sutured using C-3 6-0 surgical plain gut suture (Hu-Friedy®) and 
the skin was sutured closed using absorbable C-1 5-0 surgical plain gut suture (Hu-
Friedy®).  
 Using an animal scale (Adam Equipment®), post-surgery weight was recorded. 
Mice were monitored for 20 minutes to observe the animal was walking correctly. Post-
operative care was provided for 48 hours post-surgery. Mice received 0.10mL of 
buprenorphine and 0.01mL of enrofloxacin.   
 
Distraction Procedure 
Distraction phase started at day 7 and continued for 10 days. A distraction tool 
was used with the distraction device producing a quarter turn twice daily (0.15 mm/day) 
until the target date. The total length of distraction was 1.5mm. 
 
Control Injections 
The corn oil was sterile filtered using a 0.22µm filter unit (Millex®GP) and 10mL 
syringe (BD®) and aliquoted into sterile 1.8mL cryotubes (Model: Nunc®, Sigma-
Aldrich). The corn oil was stored in a -20ºC freezer to ensure sterile conditions. Controls 
received IP injections of sterile corn oil starting at day 6 and continued throughout the 
experiment (3x per week).   16 
 
 
Tamoxifen Injections 
Tamoxifen was dissolved in corn oil at a concentration of 10mg/mL in a 50mL 
conical tube by using a sonicator. Each sonication cycle consisted of 30 seconds on and 5 
seconds off. Sonication continued until the tamoxifen was fully dissolved in the corn oil. 
The solution was then sterile filtered using a 0.22µm filter unit (Millex®GP) and 10mL 
syringe (BD®). Tamoxifen dissolved in corn oil were aliquots of into sterile 1.8mL 
cryotubes (Model: Nunc®, Sigma-Aldrich) and stored in -80ºC freezer to ensure sterile 
solutions at injections. 
 Mice received tamoxifen by IP injection starting at day 6 and continued 
throughout the experiment (3x per week).  Tamoxifen, at 10mg/mL in corn oil, was 
injected at 1% v/w of the mouse. 
 
Harvest Procedure 
 Mice were euthanized using carbon dioxide followed by cervical dislocation.  
Plain film X-rays of the distracted limb were collected using the Faxitron® MX-20 
Specimen Radiography System. Images were collected at 30kV for 40 seconds at a 
distance of 15 cm. After X-ray, the sample was collected by isolating the femur and 
removing the distraction device. The contralateral femur was also collected. For RNA 
samples, the superficial muscle was removed and only the distraction gap was kept from 
the femur as the femoral heads were removed. Muscle samples were taken from the 
muscle that was adjacent to the femur. All samples for RNA analysis were flash frozen in  17 
 
liquid nitrogen and stored at -80°C. For vessel perfusion samples, the femur and 
surrounding muscle were kept intact. 
  
RNA Extraction 
 For these studies a Qiagen Tissue Lyser II system was used for rapid tissue lysis 
and RNA extraction. Cold adaptors were used throughout lysing procedure to prevent any 
RNA degradation. Samples of femur or muscle were added to sterile 2mL Eppendorf tube 
filled with 0.75mL of Qiazol Lysis Reagent. Samples were then snap frozen by placing 
each tube in liquid nitrogen for 10 to 20 seconds to allow the stainless steel bead to 
pulverize the sample in its solid form. Tubes were quickly placed into the Qiagen Tissue 
Lyser II sample holders, added one stainless steel bead, and capped the holders with its 
adaptors. The Qiagen Tissue Lyser II ran for 2 minutes at a frequency of 30 Hz for each 
cycle. If the bone is not fully ground, the cycle is repeated again. If the sample started to 
thaw, it was taken out of the holder, snap frozen for 10 seconds, and lysed until the frozen 
solid turns into a whitish pink solution. 
 Each sample was transferred into a new autoclaved 2mL filled with 1.0mL of 
Qiazol Lysis Reagent, and placed on ice for a minimum of 2 minutes to allow the lysis 
reagent to allow further lysing of tissue. Then 200µL of chloroform was added to the 
solution, thoroughly vortexed and placed on ice for 2 minutes. The solution was vortexed 
again and placed it in the 5804R centrifuge (Eppendorf®) at 14,000 rpm at 4ºC for 15 
minutes to separate the aqueous and organic layers. 
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 The aqueous phase was transferred to another autoclaved 2mL tube then added an 
equal volume of isopropanol. The tube was gently inverted until the solution is clear to 
allow nucleic acid and other salts to fully dissociate into the solution. The solution was 
centrifuged in the 5804R centrifuge (Eppendorf®) at 14,000 rpm at 4ºC for 30 minutes to 
generate a pellet. 
 Afterwards, the supernatant was discarded and 500µL of 70% ethanol was 
aliquoted to the tube to wash the RNA. The samples were then spun at 14,000 rpm at 4ºC 
for 5 minutes in the 5804R centrifuge. An additional wash step involving 70% ethanol 
was used to ensure the RNA sample was free of impurities. Samples were then dried for 
30 minutes by leaving the tubes upside down on a kimwipe (Kimberly-Clark®) with the 
lid opened. The pellet was then resuspended in 30 to 100µL of RNase-free H2O 
depending on the size of the pellet.  
To analyze the quantity and quality of the RNA, the DU® 530 Life Science 
UV/Vis spectrometer (Beckman Coulter™) was used. The program used was the 260/280 
assay program under the Nucleic Acid category. After blanking the spectrometer with 
100µL of dH2O, a solution of 1µL of RNA from each sample in 99µL of dH2O was 
placed in the cuvette to determine the λ260 value and λ260/ λ280 ratio. The λ260 value 
indicated the concentration of RNA (µg/µL) of the sample. The λ260/ λ280 ratio designated 
the quality of the RNA.  
Furthermore, to ensure that the RNA samples were not degraded, the samples 
underwent gel electrophoresis. A 1.5% agarose gel, made from 100mL of 1X TAE 
buffer, 1.5g of agarose, and 10µL of GelStar™ Nucleic Acid Gel Stain (Lonza®) was 
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used for this procedure. The gel was casted into a gel holder in the horizontal 
electrophoresis chamber (Bio-Rad®). Once the gel solidified, the gel was immersed in 1X 
TAE buffer and each well was loaded 10µL of RNA solution. Each RNA solution 
consisted of 7µL of dH2O, 2µL of loading dye, and 1µL of RNA. The gel was run at 
110V using the electrophoresis machine (Bio-Rad®) for 1 hour to 1 hour and 15 minutes 
to allow optimal separation of bands. Using a UV machine (Alpha Innotech Corporation) 
and ImagePro Plus software, the bands were visualized under UV light and the gel was 
imaged using 0.4 second to 0.6 second of exposure time depending on the brightness of 
the bands. 
 
cDNA Procedure 
RNA (2µg) was diluted with RNase-free H2O to a total volume of 10.4µL in a 
0.2mL PCR tube (Eppendorf®). Then a master solution of reagents was added to each 
RNA sample which consisted of 6.61µL of MgCl2, 6.0µL of dNTP mix, 3.0µL of 10X 
Reverse Transcriptase Buffer, 1.5µL of Random Hexamers, 0.6µL of RNase Inhibitor, 
and 1.89µL of Taqman Reverse Transcriptase for a total volume of 30 µL. The solution 
was thoroughly vortexed, spun down, and underwent PCR reaction using the 
Mastercycler personal wells (Eppendorf®). The program used for PCR was program #11 
which consisted of a denaturing stage of 10 minutes at 25ºC followed by an annealing 
stage of 60 minutes at 37ºC then an elongation stage of 5 minutes at 95ºC and finally the 
PCR machine held the solution at 4ºC. 
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Quantitative Polymerase Chain Reaction (qPCR) 
cDNA was diluted with RNAse free H2O to a ratio of 1:50 with the total volume 
of 500µL. Using the repeater pipette (Eppendorf®) with a 5mL syringe (BrandTech), 
10µL of Universal Master Mix and 1µL of the appropriate primer were placed into each 
well of the 96 well PCR plate (USA Scientific®). 9µL of the 1:50 diluted cDNA were 
added into each well using the multi-channel pipettor (BrandTech). The PCR plate was 
covered with clear film and centrifuged for 2 minutes at 1200 rpm. Each sample was run 
in duplicate.  
ABI 7700 Sequence Detector® (Applied Biosystems) was used to run the qPCR 
reaction. The 7300 software program, used in conjunction with the ABI 7700 Sequence 
Detector, repeated the following cycle 40 times. Each cycle consisted of 2 minutes at 
50ºC then 10 minutes at 95ºC followed by 15 seconds at 95ºC then 1 minute at 60ºC. All 
CT values were analyzed using the delta delta CT method which uses two normalizations, 
one to the control gene, 18s and two, normalizes the experimental samples to the control 
group (Livak & Schmittgen, 2001). 
 
Primers used for Real Time Polymerase Chain Reaction (RT-PCR) 
 Listed in Table 3 are genes this study examined to describe how osteogenesis was 
affected by BMP2 knockout in SMA positive cells. 
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Gene Known Function/Properties ID Number 
Bone Production Genes 
BMP2 Potent agonist for osteogenesis Mm01340178_ml 
ID1 Downstream of BMP2 signaling 
pathway; increase bone mass 
Mm00775963_gl 
Smad6 Involved in the Smad pathway 
initiated by BMP2 
Mm00484738_ml 
Smad7 Involved in the Smad pathway 
initiated by BMP2 
Mm00484740_ml 
Prx1 Osteoprogenitor stem cell 
marker 
Mm00440932_ml 
Osteocalcin Binds tightly to calcium and 
apatite 
Mm00649782_gl 
Osterix Involved in osteoblast 
differentiation 
Mm04209856_ml 
Bone Sialoprotein (BSP) Binds tightly to hydroxyapatite Mm00492555_ml 
DMP1 Produces dentin matrix acidic 
phosphoprotein 1 
Mm01208363_ml 
SOST Inhibitor of bone growth 
through inhibition of Wnt 
signaling 
Mm00470479_ml 
RUNX2 Osteoblastic differentation Mm00501580_ml 
Bone Resorption Genes 
Cathepsin K Protein involved in osteoclast 
function 
Mm00484039_ml 
Trap5b Bone resorption marker Mm00475698_ml 
RANKL Activating factor for osteoclast 
differentiation; increase bone 
resorption 
Mm00441908_ml 
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Chondrogenic Genes 
Sox9 Part of skeletal development 
through association with 
chondrogenesis 
Mm00448840_ml 
Acan Proteoglycan component of 
cartilage 
Mm00545794_ml 
Col10a Type X collagen from 
hypertrophic chondrocytes 
Mm00487041_ml 
Angiogenic Genes 
Ve-cadherin Cadherins present on 
endothelial cells 
Mm00486938_ml 
VegfA Involved in angiogenesis, 
endothelial growth, and 
vasculogenesis 
Mm00437304_ml 
VEGFR2 Receptor for VegfA, VegfC, 
and VegfD. Involved in 
multiple angiogenesis activities. 
Mm00440099_ml 
Pecam1 Cell adhesion marker involved 
diapedesis during inflammation; 
primarily used to display 
presence of endothelial cells 
Mm01242584_ml 
Endomucin Inhibits ability for cells to bind 
to extracellular matrix by 
inhibiting focal adhesion 
assembly 
Mm00497495_ml 
Table 3: Genes related to bone production, bone resorption, chondrogenesis, and angiogenesis.  
Micro-Computed Tomography (micro-CT) for Bone Evaluation 
Scanco Medical µCT 40 was used to scan the region of interest which included 
the distraction gap with additional space distally and proximal to the gap.  Typically the 
scanned region was approximately 700 slices and scanned at a resolution of 9µm. The 
control file used was named, DBM_Vessels, which dictates the proper parameters for the  23 
 
scanner at the resolution of 9µm which are 70kV, 114 mA and 300 seconds of integration 
time.  
In the Scanco microCT 40 analysis software, samples were contoured by drawing 
lines as closely to the sample as possible that included bone and surrounding callous. Any 
cortical bone along with the medullary cavity was excluded from the contouring to ensure 
that the bone evaluation only determined newly formed bone. When the 3D bone 
evaluations were run, the threshold used was determined by the image processing 
language threshold determination script, developed by Scanco Medical System. It 
calculated an optimal threshold for the contoured area for trabecular bone. The average 
threshold throughout all samples were 160. The evaluation generated a bone volume 
(BV) which indicated the amount of bone present per cubic centimeter and total volume 
(TV) which was the total contoured volume in cubic centimeters. 
 
Vessel Analysis 
 Described below in the following three subsections are the methods used for 
investigating vessel formation involving vessel perfusion, µCT, and de-calification. 
Vessel Perfusion 
After euthanizing the mouse with CO2, plain x-ray images were obtained with the 
Faxitron MX-20 Specimen Radiography System of the distracted limb using the same 
settings as the harvest procedure. The mouse was placed in a supine position on top of a 
Styrofoam platform that was angled at 30º. A vertical incision of the skin was made 
through the median plane starting from the abdominal cavity towards the neck followed  24 
 
by two horizontal incisions that ran parallel with the bottom of the rib cage using a pair of 
scissors. The visceral peritoneum at the bottom of the sternum was raised by using 
forceps and produced a hole using scissors. 
A pneumothorax was created by cutting a pin-size hole in the diaphragm using 
small scissors. Using the same pair of scissors, the diaphragm was separated from the rib 
cage and clipped the two ends of the rib cage parallel to the sternum. The ribcage was 
then lifted and pinned back using an 18 gauge needle (BD®) exposing the cardiac cavity.  
The exposed heart was used as the landmark to locate the vena cava which was snipped 
to create a drainage hole for the perfusion solution. The left ventricle was pierced by a 25 
gauge butterfly needle (BD®), and 10mL of 10% phosphate buffered formalin solution 
was injected using a 10mL syringe (BD®).  
Two different contrast agents were used in these studies. 
Method 1  
In these studies, MicroFil solution was prepared using 9mL of MicroFil and 
500µL of curing agent (Morgan et al., 2012). 6 mL of the MicroFil and curing agent 
mixture was injected into the mouse using 1mL TB syringes (BD®). The samples were 
then fixed for 3 days in PFA and washed with 1X PBS.   
Method 2 
For the barium model, a solution was made of 6mL of Ba (25% w/v), 12mL of 1X 
PBS, and 12mL of gelatin/PBS (Roche et al., 2012). We made the gelatin/PBS mixture 
by adding 1.5g of gelatin to 50mL of 1X PBS in a 50mL conical tube. The mixture was 
heated in a 100ºC water bath until it liquefied.  The solution was allowed to cool to ~ 
 25 
 
37oC. The animals were injected with 12mL of the barium/gelatin solution to ensure 
consistent amount of vessel perfused between each sample. The samples were then fixed 
for three days in PFA and washed with 1X PBS before being embedded in agarose gel. 
Micro-Computed Tomography (micro-CT) for Vessel Evaluation 
Stainless steel wires (0.012 inch Standard Kobayashi Hooks) were threaded 
through the tissue near the proximal femoral head. Additional wires were inserted to 
mark the region of interest. The samples was then embedded in 2% agarose (w/v) to 
maintain the samples in place within the scanning tubes.  
Using the Scanco Medical µCT 40, the region was scanned between the two pin 
placements which included the distraction gap. Typically the scanned region consisted of 
700 slices. The control file used was DBM_Vessels with a resolution of 9µm which are 
70kV, 114 mA and 300 seconds of integration time. Once the scan and reconstruction 
completed, images were contoured by drawing a circle in the Scanco microCT 40 
analysis software that included bone, vessels, and surrounding tissue. The 3D renderings 
were constructed using a lower threshold of 160 and a zoom of 150%. This 160 threshold 
was utilized because the average threshold for cortical bone to be approximately 220 and 
trabecular bone’s average threshold was 160. The 160 threshold included vessel elements 
because the contrast agent used typically had a threshold greater than 160.  
Decalcification for Vessel Scanning 
 Bones were decalcified using a 14% (w/v) EDTA solution. The tissue samples, 
previously embedded in agarose gel, were placed in perforated 50mL conical tubes.  26 
 
Perforations were made in the tube walls by an 18 gauge needle (BD®) and further 
enlarged by drilling a #15 scalpel blade into it (Bard-Parker®). The tubes were immersed 
along with a stir bar in EDTA solution for four days on top of a stir plate (VWR®) set at 
20 rpm in a 4oC room to allow total removal of mineralized tissue.   
 
Statistical Methods 
 Using the JMP program, statistical analysis was performed on the qPCR Ct values 
using nonparametric Wilcoxon method due to the small sample size. Sample averages, 
standard deviation, and standard error were obtained for each group. Standard error bars 
were included in graphs generated for mRNA expression of selected genes.   
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RESULTS 
qPCR for Distraction Gap 
RNA was isolated from samples that were collected from the distraction gap of 
the femur and the muscle directly adjacent to the distracted femur at days 3, 7, 12, 24, 
and 31. Bone formation was assessed by the analysis of a cassette of genes that defines 
the progression of osteogenic differentiation. In Figure 7, RUNX2 was raised for BMP2 
knockout at day 12, 24 and 31 compared to the control. The control for RUNX2 had same 
expression values at day 17 with the knockout but dropped afterwards. Moreover, several 
bone production genes such as osteocalcin, osterix, BSP, DMP1, and Smad6 were 
increased for the BMP2 knockout compared to the control for all time points. 
Osteocalcin’s difference between the control and knockout steadily increased from day 7 
to day 31. Whereas Osterix showed increased expression between the control and 
knockout dipped in day 31 these results were not significantly different.   Although BSP 
was elevated throughout all time points in the femur for the BMP2 knockout, it did not 
share a similar decrease in expression displayed by the control. DMP1’s differences grew 
larger between the control and BMP2 knockout as the time points increased. There was 
no peak for SOST in the BMP2 knockout at day 12. SOST expression was identical 
between the two groups at day 17 and 24 but the BMP2 knockout showed a decreased 
level by day 31. BMP2 expression was higher for the knockout during the distraction 
phase and at the middle of the consolidation phases of the experiment. Smad6 showed 
similar trends between control and BMP2 knockout where the BMP2 knockout was 
higher in expression throughout all time points. However, Smad7 showed a different 
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profile in which the knockout had lower levels of expression compared to the control. 
ID1 levels were elevated at all time points for the knockout. The knockout for Prx1 gene 
demonstrated an earlier spike in expression to the control, but increased expression at day 
31. 
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Figure 7: Distraction Gap qPCR Results for Bone Production. The black line represents the control (corn oil) and 
the grey line represents the experimental (tamoxifen-induced BMP2 knockout). RUNX2, Osteocalcin, Osterix, BSP, 
DMP1, SOST, Smad6, Smad7, BMP2, ID1 are bone producing factors. Prx1 is an osteoprogenitor stem cell marker. 
The error bars shown are standard error. There are no statistical differences (p>0.05) between control and BMP2 
knockout for all bone producing genes. The sample size for day 3 was n=3, day 7 was n=3, day 12 was n=6, day 17 was 
n=11, day 24 was n=6, and day 31 was n=6.  
Bone resorption genes are depicted in Figure 8. Trap5b and RANKL showed 
higher expression levels at day 12 for the BMP2 knockout but was quickly eclipsed by 
the control at day 17. The spike of the control at day 17 eventually fell below the 
knockout at day 31. Cathepsin K was elevated for the experimental groups compared to 
the control throughout all time points. 
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Figure 8: Distraction Gap qPCR Results for Bone Resorption. The black line represents the control (corn oil) and 
the gray line represents the experimental (tamoxifen-induced BMP2 knockout). Trap5b, Cathepsin K, and RANKL are 
bone resorption genes. The asterix indicates statistical difference at that time point between the control and BMP2 
knockout. At day 17, there is statistical difference for Trap5b and RANKL between the control and BMP2 Knockout 
with p<0.05. The rest of the time points for Trap5b, Cathepsin K, and RANKL have no statistical difference (p>0.05) 
between the control and BMP2 knockout. The sample size for day 3 was n=3, day 7 was n=3, day 12 was n=6, day 17 
was n=11, day 24 was n=6, and day 31 was n=6. 
 
The effect of BMP2 knockout in SMA positive cells was also measured for 
chondrogenesis which is shown in Figure 9. Col10a profile showed a smaller and earlier 
peak for the BMP2 knockout than the control. The large difference in magnitude for 
peaks of the control to the knockout is 21577 fold, which is statistically significant. Acan, 
another gene for chondrogenesis, follows the same pattern as Col10a in that there was an 
earlier peak of expression for the BMP2 knockout samples. However, the difference in 
peak magnitude was not as dramatic as Col10a. Sox9 also exhibited an earlier spike in 
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expression but was not as pronounced as seen in Col10a and Acan. For all three genes, 
the expression drops after the peak. 
 
Figure 9: Distraction Gap qPCR Results for Chondrogenesis. The black line represents the control (corn oil) and 
the gray line represents the experimental (tamoxifen-induced BMP2 knockout). Sox9, Acan, Col10a are important 
components for chondrogenesis. The error bars shown are standard error. The asterix indicates statistical difference at 
that time point between the control and BMP2 knockout. At day 17, there is statistical difference for Col10a between 
the control and BMP2 Knockout with p<0.05. The rest of the time points for Sox9, Acan, and Col10a have no 
statistical difference (p>0.05) between the control and BMP2 knockout. The sample size for day 3 was n=3, day 7 was 
n=3, day 12 was n=6, day 17 was n=11, day 24 was n=6, and day 31 was n=6. 
 
The effects of BMP2 knockout in SMA cells for angiogenesis in the distraction 
gap gene profiles are shown in Figure 10. The SMA gene profile showed that conditional 
knockout of BMP2 did not affect its function in the femur. There appeared to be a slight 
decrease in angiogenesis in the femur due to diminished levels of ve-cadherin and 
VEGFR2 specifically starting at day 17. However, there was no significant difference for 
VegfA, the main marker for angiogenesis, even at day 31 which had a 1 fold difference. 
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Figure 10: Distraction Gap qPCR Results for Angiogenesis. The black line represents the control (corn oil) and the 
gray line represents the experimental (tamoxifen-induced BMP2 knockout). SMA, Ve-Cadherin, VegfA, and VEGFR2 
are indicative of angiogenesis. The error bars shown are standard error. All time points for SMA, Ve-Cadherin, VegfA, 
and VEGFR2 have no statistical difference (p>0.05) between the control and BMP2 knockout. The sample size for day 
3 was n=3, day 7 was n=3, day 12 was n=6, day 17 was n=11, day 24 was n=6, and day 31 was n=6. 
 
qPCR for Muscle 
The gene profiles of muscle for bone producing genes, BMP2 and ID1, are shown 
below in Figure 11. Both genes were affected by the BMP2 knockout as differences are 
seen as early as day 7 of the experiment with decreased expression for BMP2 and ID1. 
The knockout for both BMP2 and ID1 gene expressions steadily decreased towards day 
31 time point. For the control, BMP2 had a small surge in expression in the muscle at day 
17 whereas ID1 spikes at day 12 and then both decreased approximately linearly towards 
day 31. 
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Figure 11: Muscle qPCR Results for Osteogenesis. The black line represents the control (corn oil) and the gray line 
represents the experimental (tamoxifen-induced BMP2 knockout). The error bars shown are standard error. The asterix 
indicates statistical difference at that time point between the control and BMP2 knockout. At day 17, there is statistical 
difference for BMP2 and ID1 between the control and BMP2 Knockout with p<0.05. The rest of the time points have 
no statistical difference (p>0.05) between the control and BMP2 knockout. The sample size for day 3 was n=3, day 7 
was n=3, day 12 was n=6, day 17 was n=11, and day 31 was n=6. 
Assessment of anigogenic mRNA expression in the muscle is seen in Figure 12.  
A comparison of the genes expression showed every  angiogenesis marker decreased 60-
90% with the BMP2 knockout. The VEGFR2 profile showed decreased expression in the 
mice in which BMP2 was conditionally deleted in the SMA expressing cells with the 
largest difference at day 17 with a difference of 2 fold between the control and knockout. 
Interestingly, decreased levels of expression for endomucin were seen in the muscle 
compartment even though it had previously been selectiviely associated only with vessels 
in the marrow space.  Pecam1 levels were also  decreased for the BMP2 knockout with 
its largest difference at day 12. This difference was reduced onwards to a difference of 1 
fold at day 31. Finally an assesssment of ve-cadherin expression was also shown to be 
reduced as well in the BMP2 knockout which suggests a diminish in angiogenesis in the 
muscle comaprtment. The most drastic difference occured at day 12 between the control 
and knockout and the difference stays relatively constant throughout the experimental 
timeline. 
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Figure 12: Muscle qPCR Results for Angiogenesis. The black line represents the control (corn oil) and the gray line 
represents the experimental (tamoxifen-induced BMP2 knockout). The error bars shown are standard error. All time 
points for VEGFR2, Endomucin, Pecam1, and Ve-Cadherin have no statistical difference (p>0.05) between the control 
and BMP2 knockout. The sample size for day 3 was n=3, day 7 was n=3, day 12 was n=6, day 17 was n=11, and day 
31 was n=6. 
 
X-Ray 
 The development of bone during DO in control and experimental mice was 
initially assessed by plain X-ray film. Presented below in Figure 13 are x-ray images of 
the distraction device attached to the distracted femur after euthanizing the mice but 
before harvesting the limbs for additional procedures. There were no significant 
differences in bone formed at the distraction gap between the plain X-rays for control and 
BMP2 knockout samples for day 7 and 17. At day 24, bone was present in the distraction 
gap of the control and absent in the tamoxifen induced BMP2 knockout. At day 31, the 
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control sample’s bone looked to be almost completely repaired whereas in the BMP2 
knockout the distraction gap is still not filled with bone.   
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Figure 13: DO X-ray Results. X-ray results at different time points. The control received corn oil injections and the 
experimental received tamoxifen (10mg/mL) injections. These images are representative of all DO procedures.  
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µCT Bone Evaluation 
 Three dimensional analysis of bone formation by µCT was completed on -
samples without perfusion and were evaluated for the amount of bone present in both 
control and knockout samples. Shown below in Figure 14, there was no definitive 
difference between the knockout and the control for the two dimensional slicer viewer. 
Position Control Experimental 
Proximal at the 
region below the 
trochanter 
  
Mid-diaphyseal 
  
Distal to the knee 
  
Figure 14: Day 31 2D µCT Results for Bone Evaluation. Day 31 experimental µCT results of DO procedure with 
corn oil injections (middle column), and tamoxifen injections (far right column). 
Quantitative data for bone volume (BV) for control and BMP2 knockout samples 
from the µCT bone scans are shown below in Figure 15 and Figure 16. The difference 
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between the BV values for the control and BMP2 knockout indicated that the control had 
slightly more bone formed with 2.2581 mm3 to knockout with 1.9492 mm3 as shown in 
the Direct (No Model) cell. It is also shown that the control has a BV/TV value of 0.3539 
which is higher than the knockout’s BV/TV ratio of 0.1376. 
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Figure 15: µCT Bone Evaluation for Control. The TV, BV and BV/TV values are presented in the Direct (No 
Model) cell. Image is representative of all samples. 
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Figure 16: µCT Bone Evaluation for BMP2 Knockout. The TV, BV and BV/TV values are presented in the Direct 
(No Model) cell. Image is representative of all samples.   
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µCT Microfil Vessel Perfusion 
Two dimensional slices of day 31 pre-decalcified samples for both control and 
tamoxifen-induced BMP2 knockout were taken as shown in Figure 17. The image 
sequence started at proximal at the region below the greater trochanter, mid-diaphyseal, 
and distal to the knee. However in the two dimensional images, it was difficult to gain a 
qualitative assessment of the amount of vessel present in each sample. Therefore, three 
dimensional renderings of pre-decalcified samples were obtained as shown below in 
Figure 18Figure 18. These images clearly showed a difference between the control and 
the experimental samples in the vessels, particularly the capillaries, in which there was a 
smaller number of capillaries in the control compared to the tamoxifen-induced BMP2 
knockout in SMA cells.   
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Figure 17: Day 31 2D µCT Results for Vessel Perfusion. Day 31 experimental µCT results of DO procedure with 
corn oil injections (middle column), and tamoxifen injections (far right column). 
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Figure 18: Day 31 3D Pre-decalcified µCT Results. Day 31 experimental µCT results of DO procedure with corn oil 
injections (left images), and tamoxifen injections (right images). The rotation angle has no anatomical reference. 
  To further differentiate between bone and vessels, images of 3D renderings were 
taken after the decalcification procedure as shown in Figure 19. The decalcification 
procedure worked as intended as the vast majority of the amount of vessels and quality of 
vessels did not appear to be significantly altered. These results however were in contrast 
to the mRNA findings suggesting that the Microfil method may not be technically 
sufficient to image the smallest vessels that are present in the tissue. This conclusion was 
also supported by the gross appearance of the perfused tissues in the experimental groups 
which showed a failure to obtain complete perfusion in the distal appendages due to lack 
of the observed yellow color in these vessels in the BMP2 knockout experimental group.  
It was also noticed that in these animals often the back pressure generated by the 
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perfusion of the viscous Microfil reagent led to leakage of the reagent from the heart and 
descending aorta during perfusion.  
 
Figure 19: Day 31 3D Post-decalcified µCT Results. Day 31 experimental µCT results of DO procedure with corn oil 
injections (left images), and tamoxifen injections (right images). The rotation angle has no anatomical reference. 
 
µCT Barium Vessel Perfusion 
 Because of the suspected technical problems with the Microfil method, a different 
approach was assessed using barium solution mixed with dissolved collagen gelatin prior 
to polymerization.  Since prior to polymerization, the gelatin solution is much less 
viscous than the silicon Microfil solution as well as taking much longer to set up in the 
vascular during perfusion this approach leaded to much lesser back pressure in the 
vasculature during perfusion as well as allows for much greater volumes of the solution 
to be perfused throughout the animal. The barium model results showed a much greater 
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reproducibility across samples and it produced a much better resolution of the smaller 
vessels than the Microfil method.  A representative comparison of the two methods is 
shown in Figure 20. The two samples demonstrate the large amount of vessels perfused 
using 0.5g/mL of Ba in gelatin solution. Shown in Figure 21 is a comparison of barium 
perfused samples to Microfil perfused samples. 
 
 
Figure 20: Barium Perfused Samples. Both images are from the barium perfusion model. The barium concentration 
used for both samples was 0.5g/mL. This image portrays the reproducibility across samples. 
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Figure 21: Comparison of Barium to Microfil. The left image is a perfused sample using Microfil as the perfusing 
agent. The right image is a perfused sample using barium/gelatin as the perfusing agent. The barium model has 
enhanced vessel resolution to the Microfil, particularly at smaller  
 
Subsequently we repeated our initial results for the comparing BMP2 knockout 
mice and control mice at day 31. In this study shown in Figure 22, it is obvious that there 
is more vessel formation in the control than the tamoxifen induced BMP2 knockout. Both 
femoral arteries and neighboring arterioles are perfused which indicate equivalent amount 
of perfusion occurred for both samples. The decrease in amount of smaller vessel 
elements being perfused in these studies now indicates that there is indeed a diminished 
amount of vessel formation in the conditionally deleted mice consistent now with the 
mRNA findings.   
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Figure 22: Barium Vessel Perfusion for Control Versus BMP2 Knockout. The control (middle column images) has 
more vessels compared to the experimental (far right column images). The barium concentration used for both samples 
was 1.0 g/mL. The rotation angles have no anatomical reference. The yellow arrows indicate the distraction gap.  
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DISCUSSION 
 
The x-ray results showed that the femur is healed by day 24, half way into the 
consolidation phase, for both control and experimental groups. This was verified by the 
µCT results. The qPCR results for SMA in the femur confirmed that the Cre/loxP system 
works as intended as there is no difference between the control and the experimental. 
This was further confirmed by BMP2 levels are decreased in the muscle which confirms 
the fact that the Cre/loxP system is working as intended on SMA positive cells. However, 
BMP2 expression in the distraction gap has no clear distinction between the control and 
knockout, this might be due to the limited number of SMA positive cells located within 
the distraction gap.  
Most of the BMP2 knockout’s bone producing genes in the femur such as 
RUNX2, osteocalcin, osterix, and BSP from the qPCR results is elevated compared to the 
control in fold change especially at the late time points. Also, there are raised levels of 
Cathepsin K in tamoxifen induced BMP2 knockout which suggests higher osteoclast 
activity. This may explain why there was less bone in the knockout compared to the 
control shown in the plain X-ray and µCT bone evaluations. Furthermore, earlier 
formation of cartilage in the femur is depicted by early spikes in expression for Col10a 
and Acan profiles. This may suggest that the cartilaginous callus appears earlier but is not 
as large for the knockout due to the differences in peak magnitudes of RNA levels 
especially for Col10a.  
The difference in angiogenesis between muscle and bone is best represented by 
the ve-cadherin and VEGFR2 gene profiles. It is obvious that angiogenesis in the muscle  50 
 
decreased as seen in reduced levels for both ve-cadherin and VEGFR2 expression at all 
time points when tamoxifen was present. This was further validated by diminished levels 
of expression for both endomucin and Pecam1. However, the level of gene expression for 
ve-cadherin and VEGFR2 in the bone is not as pronounced as it is in the muscle. The 
largest difference in magnitude for gene expression between the control and BMP2 
knockout for muscle was 5.11 for ve-cadherin, and 2.20 for VEGFR2 at day 17. The bone 
also had the largest gap between the control and BMP2 knockout at day 17. However, the 
magnitude of the gap was 2.95 for ve-cadherin, and 1.33 for VEGFR2. Interestingly, ve-
cadherin and VEGFR2 levels of expression drastically dropped at day 24 for the femur. 
This feature was absent in the muscle although the difference diminished slightly at day 
24 and day 31. These results suggested that the femur was not as affected by the BMP2 
knockout in SMA cells as to the muscle but angiogenesis was slightly inhibited. 
When we examined VegfA in the bone, gene expression levels at day 24 was 
higher for the BMP2 knockout than the control by 1.17 fold. This suggests that the callus 
is signaling for vessel formation to allow further bone repair as cells and other growth 
factors outside of the distraction gap are unable to reach the underdeveloped callous. 
However, since VEGFR2 was reduced at day 17 and only slightly recovered at day 24, 
the endothelial cells were unable to respond to high levels of VegfA to undergo sprouting 
angiogenesis. 
To further support the idea of reduced angiogenesis, µCT results for the Microfil 
model showed there is an increase in vessels, especially smaller vessels such as 
capillaries for the control. Perhaps this suggests a secondary pathway where angiogenesis 
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occurs as there is a discrepancy in µCT and qPCR. However, this discrepancy was to 
technical issues as vessels bursting under elevated back pressure it was a common 
occurrence when using the Microfil model. The issue was resolved when the Microfil 
model was replaced by the barium/gelatin model. The greatly lower viscosity of the 
barium/gelatin model produced less pressure as perfusion proceeded which allowed a 
much greater volume of barium to perfuse the samples compared to the Microfil model. 
All barium perfused samples had comparable vascular perfusions between specimens 
because not only was the femoral artery consistently filled but also the larger vessels 
branching from the femoral artery were visible to the naked eye. This feature was rarely 
observed when perfusing with Microfil. The barium model undoubtedly showed that 
there is indeed a decrease in vessels for the tamoxifen induced BMP2 knockout to the 
control. The µCT bone evaluation data further confirmed a decrease in bone formed in 
the control than the knockout. Therefore, it seems that when BMP2 is knocked out in 
SMA cells, it inhibits angiogenesis which then causes a decrease in osteogenesis. 
Future Goals 
 We hope to continue barium perfusions as the results are very promising due to 
their consistency and increase in vessels perfused. In addition to our µCT scans, we plan 
to complete vessel imaging to quantify the total volume of vessels and vessel types to 
compare the control to the experimental. Also, we plan to finish our µCT bone 
evaluations with to quantify bone volume data to compare control to tamoxifen-induced 
BMP2 knockout samples. 
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Specific studies will also be undertaken to examine additional genes for both femur and 
muscle environment to capture a more complete picture of how BMP2 deletion in the 
surrounding muscle, muscle compartments effects angiogenesis. Finally, we will 
complete the histological analysis to provide further visualization of angiogenesis, 
chondrogenesis and osteogenesis within the various tissue compartments effected by 
distraction.  
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